Merck, Johnson & Johnson Announce Acquisitions to Bolster Respective Oncology Pipelines

Merck has acquired Harpoon Therapeutics with its clinical stage T-cell engager, whereas Johnson & Johnson acquired Ambrx Biopharma with its expertise in next generation antibody drug conjugates and targeted oncologic therapies.

Source link
#Merck #Johnson #amp #Johnson #Announce #Acquisitions #Bolster #Respective #Oncology #Pipelines